Keyphrases
Gene Therapy
100%
Immune Stimulation
100%
Myeloid-derived Suppressor Cells
100%
Immunosuppressive Myeloid Cells
100%
Glioma Microenvironment
100%
Thymidine Kinase
60%
FMS-like Tyrosine Kinase 3 (FLT3)
60%
Immunosuppression
40%
T Cells
40%
Programmed Death-ligand 1 (PD-L1)
40%
Host Immune Response
20%
Glioma
20%
Antitumor Immune Response
20%
Tumor-specific
20%
Antigen-specific
20%
Standard of Care
20%
Herpes Simplex
20%
Immune Checkpoint Blockade
20%
Cell-mediated
20%
Inducible Nitric Oxide Synthase
20%
Immunotherapeutic Approaches
20%
IL-4Rα
20%
Cell Depletion
20%
CD80
20%
Median Survival
20%
Long-term Survivors
20%
Multiple Strategies
20%
Arginase
20%
Fms-like Tyrosine kinase-1
20%
CD-8
20%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
20%
Tumor-infiltrating Immune Cells
20%
Checkpoint Blockade
20%
Medicine and Dentistry
Gene Therapy
100%
Ganglioglioma
100%
Myeloid-Derived Suppressor Cell
100%
Myeloid Cell
100%
Immunosuppressive Drug
100%
Thymidine Kinase
60%
Neoplasm
40%
Immunosuppressive Treatment
40%
Programmed Death 1 Ligand 1
40%
Immune Response
20%
Cancer
20%
Antigen Specificity
20%
Specific Tumor
20%
Immunocompetent Cell
20%
Protein Tyrosine Kinase
20%
CTLA-4
20%
Herpes Simplex
20%
Inducible Nitric Oxide Synthase
20%
Immune System
20%
Immune Checkpoint Blockade
20%
CD8 Antigen
20%
Arginase
20%
Immunotherapy
20%
Immunology and Microbiology
Immunosuppressive Drug
100%
Myeloid-Derived Suppressor Cell
100%
Myeloid
100%
Immunosuppression
40%
Programmed Death 1 Ligand 1
40%
Immune Checkpoint Blockade
20%
Herpes Simplex
20%
Immune Response
20%
Antigen Specificity
20%
Immunocompetent Cell
20%
CD8
20%
CD80
20%
CTLA-4
20%
Immunotherapy
20%
Immune System
20%
Tyrosine
20%
Nitric Oxide Synthase
20%
Biochemistry, Genetics and Molecular Biology
Gene Therapy
100%
Myeloid
100%
Thymidine Kinase
50%
Tyrosine Kinase
16%
Immune Checkpoints
16%
Immunocompetent Cell
16%
Immune Response
16%
Antigen Specificity
16%
CD80
16%
Receptor Tyrosine Kinase
16%
CD8
16%
Arginase
16%
CTLA-4
16%
Nitric Oxide Synthase
16%